Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels

被引：3

作者：

Arachchillage, Deepa R. J. ^{[1
]}

Efthymiou, Maria ^{[1
]}

Lawrie, Andrew S. ^{[1
]}

Machin, Samuel J. ^{[1
]}

Mackie, Ian J. ^{[1
]}

Cohen, Hannah ^{[1
,2
]}

机构：

[1] UCL, Haemostasis Res Unit, Dept Haematol, London WC1E 6HX, England

[2] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

来源：

THROMBOSIS AND HAEMOSTASIS | 2014年 / 112卷 / 02期

关键词：

FACTOR-XA INHIBITOR;

D O I：

10.1160/TH14-01-0050

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：421 / 423

页数：3

共 11 条

[1] Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology [J].

Baglin, Trevor ;

Keeling, David ;

Kitchen, Steve .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (04) :427-429

[2] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].

COCKCROFT, DW ;

GAULT, MH .

NEPHRON, 1976, 16 (01) :31-41

[3] Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban [J].

Douxfils, Jonathan ;

Tamigniau, Anne ;

Chatelain, Bernard ;

Chatelain, Christian ;

Wallemacq, Pierre ;

Dogne, Jean-Michel ;

Mullier, Francois .

THROMBOSIS AND HAEMOSTASIS, 2013, 110 (04) :723-731

[4] Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays [J].

Hillarp, A. ;

Baghaei, F. ;

Blixter, I. Fagerberg ;

Gustafsson, K. M. ;

Stigendal, L. ;

Sten-Linder, M. ;

Strandberg, K. ;

Lindahl, T. L. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (01) :133-139

[5] Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement [J].

Mueck, Wolfgang ;

Borris, Lars C. ;

Dahl, Ola E. ;

Haas, Sylvia ;

Huisman, MennoV. ;

Kakkar, Ajay K. ;

Kalebo, Peter ;

Muelhofer, Eva ;

Misselwitz, Frank ;

Eriksson, Bengt I. .

THROMBOSIS AND HAEMOSTASIS, 2008, 100 (03) :453-461

[6] Rivaroxaban Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention [J].

Mueck, Wolfgang ;

Lensing, Anthonie W. A. ;

Agnelli, Giancarlo ;

Decousus, Herve ;

Prandoni, Paolo ;

Misselwitz, Frank .

CLINICAL PHARMACOKINETICS, 2011, 50 (10) :675-686

[7] More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban - early experience from King's College Hospital [J].

Patel, Jignesh P. ;

Roberts, Lara N. ;

Chitongo, Paradzai B. ;

Patel, Raj K. ;

Arya, Roopen .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (05) :717-718

[8] Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry [J].

Rohde, G. .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 872 (1-2) :43-50

[9] Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor [J].

Samama, Meyer Michel ;

Martinoli, Jean-Luc ;

LeFlem, Lena ;

Guinet, Celine ;

Plu-Bureau, Genevieve ;

Depasse, Francois ;

Perzborn, Elisabeth .

THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) :815-825

[10] Normal prothrombin time in the presence of therapeutic levels of rivaroxaban [J].

van Veen, Joost J. ;

Smith, Julie ;

Kitchen, Steve ;

Makris, Mike .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (06) :859-861

← 1 2 →